Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Randomized Midazolam Clear all
Active, not recruiting Early Phase 1 Interventional

Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology

NCT07040163
View directory record Official record
Conditions
Sedation, Interventional Radiology, Biopsy, Drainage Procedure
Interventions
ketamine, fentanyl, Midazolam
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Not applicable Interventional Results available

Dexmedetomidine Versus Midazolam for Facilitating Extubation

NCT00744380
View directory record Official record
Conditions
Critical Illness
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Satisfaction With Propofol for Out Patient Colonoscopy

NCT02937506
View directory record Official record
Conditions
Colon Cancer, IBS, Polyps
Interventions
Propofol, Fentanyl Plus Midazolam
Drug
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 28, 2026, 9:26 PM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Borderline Personality Disorder

NCT03395314
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468
View directory record Official record
Conditions
Drug Interactions
Interventions
Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

NCT04110535
View directory record Official record
Conditions
Abuse, Drug
Interventions
Remimazolam, Midazolam, Saline
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 4 Interventional

A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation

NCT00216190
View directory record Official record
Conditions
Mechanically Ventilated and Intubated Subjects
Interventions
Dexmedetomidine HCL Injection, Midazolam Injection
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 4 Interventional

Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy

NCT02193568
View directory record Official record
Conditions
Adult Brain Tumor
Interventions
Arm I (light sedation), Arm II (intubated general anesthesia), Arm II (intubated general anesthesia), Arm I (light sedation)
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 28, 2026, 9:26 PM EDT
Recruiting Phase 3 Interventional

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03016819
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions
AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 9:26 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

NCT01501123
View directory record Official record
Conditions
Agitation
Interventions
Haloperidol, Midazolam
Drug
Lead sponsor
Catholic Health East
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Darby, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D

NCT02635282
View directory record Official record
Conditions
Abscess, Pain
Interventions
intranasal ketamine, intranasal fentanyl, intranasal midazolam
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
3 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

NCT06279234
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions
Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 3 Interventional

Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery

NCT00645138
View directory record Official record
Conditions
Breast Cancer
Interventions
Paravertebral Block, General Anesthesia
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 28, 2026, 9:26 PM EDT
Withdrawn Phase 4 Interventional

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

NCT03613792
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remifentanil, Fentanyl, Midazolam, Ketamine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 28, 2026, 9:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comparative Analysis of Spinal Anesthesia Versus General Anesthesia for vNOTES

NCT05688943
View directory record Official record
Conditions
Anesthesia, Tubal Ligation
Interventions
Spinal Anesthesia, General Anesthesia
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

NCT01218620
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 28, 2026, 9:26 PM EDT
Terminated Phase 4 Interventional Results available

Treatment Study of Bipolar Depression

NCT00947791
View directory record Official record
Conditions
Bipolar Disorder
Interventions
ketamine, midazolam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

NCT02290873
View directory record Official record
Conditions
Colonoscopy
Interventions
Remimazolam, Midazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Spreading Depolarization and Ketamine Suppression

NCT02501941
View directory record Official record
Conditions
Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage, Traumatic Brain Injury
Interventions
ketamine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 28, 2026, 9:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Dexmedetomidine in Spine Surgery

NCT01850017
View directory record Official record
Conditions
Collapse of Thoracic Vertebra, Collapse of Lumbar Vertebrae
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 28, 2026, 9:26 PM EDT